WEDNESDAY, Feb. 13, 2019 — Neoadjuvant administration of programmed cell death protein 1 (PD-1) blockade seems to enhance local and systemic antitumor immune response in glioblastoma, according to a study published online Feb. 11 in
The HER2 protein, which encourages the growth of cancer cells, is present in about 20% of all breast cancers. While HER2-positive breast cancers tend to be very aggressive, today the prognosis is generally very good,
In the GDR you had to deal with sexuality and children get scared. But today? “I am, unfortunately, a big change,” says Kurt Strong. He led from 1972 onwards the Central Institute for youth research
Scientists think they have achieved the first gene editing inside the body, altering DNA in adults to try to treat a disease, although it’s too soon to know if this will help. Preliminary results suggest
A new study from Yale University found that adults take boys’ pain more seriously than pain felt by girls. Expanding on findings from a study published in 2014, the new research suggests we perceive boys as feeling more
(HealthDay)—In patients with cirrhosis, frailty is more frequently observed in those with ascites or hepatic encephalopathy (HE) and is independently associated with liver transplant wait-list mortality, according to a study published online Jan. 19 in
More than four in five men (81 percent) with prostate cancer struggle with poor sexual function following treatment for the disease, but over half (56 percent) fail to receive support, according to new research. The
The traditional medicine wheel, symbolizing balance and interconnection, can serve as a framework for improving the mental well-being of First Nations people in Manitoba. That’s the key recommendation from a mental-health study conducted by eight
Public health researchers and organizations have increasingly warned that high sugar consumption can lead to the development of several metabolic and cardiovascular diseases. A new study released by Statistics Canada this month asks whether Canadians
WALTHAM, Mass., Jan. 24, 2019 (GLOBE NEWSWIRE) — Proteon Therapeutics Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, today announced the publication